创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

王刚, 雷灿. 抗冠状病毒药物全球研发管线[J]. 药学进展, 2020, 44(2): 159-162.
引用本文: 王刚, 雷灿. 抗冠状病毒药物全球研发管线[J]. 药学进展, 2020, 44(2): 159-162.
WANG Gang, LEI Can. Global Research and Development Pipeline of Anti-coronavirus Drugs[J]. Progress in Pharmaceutical Sciences, 2020, 44(2): 159-162.
Citation: WANG Gang, LEI Can. Global Research and Development Pipeline of Anti-coronavirus Drugs[J]. Progress in Pharmaceutical Sciences, 2020, 44(2): 159-162.

抗冠状病毒药物全球研发管线

Global Research and Development Pipeline of Anti-coronavirus Drugs

  • 摘要: 2019年底,一种新型冠状病毒引起发热性呼吸道疾病(COVID-19)在武汉暴发,并迅速波及全国。冠状病毒在21世纪已经3次严重危害了人类健康。随着疫情的加剧,中国乃至全球人民均期待临床疗效明确的药物出现,缓解危机。瑞德西韦的同情用药,为患者带来了一线曙光。综述瑞德西韦以及全球抗冠状病毒研发管线中的疫苗和治疗药物,助力该类药物的全球研发,早日为人类建起防护墙。

     

    Abstract: In late 2019, a novel coronavirus caused in Wuhan a febrile respiratory illness known as COVID-19, which spread quickly across the country. Coronavirus has posed three serious threats to human health in the 21st century. With the epidemic of the virus, people in China and around the world are looking forward to the emergence of drugs with validated clinical efficacy to ease the crisis. The compassionate use of remdesivir brought a ray of light to the patients. This article reviews remdesivir, and the anti-coronavirus vaccines and therapeutic drugs in the global pipeline of research and development, in the hope of better facilitating the global development of relevant drugs so as to build a protective wall for humans against COVID-19 as early as possible.

     

/

返回文章
返回